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Abstract
Background: Ex vivo generated dendritic cells (DC) genetically modified to express secondary
lymphoid tissue chemokine (CCL-21/SLC) have been shown to stimulate potent antitumor
responses in murine models. When injected intratumorally, CCL-21 colocalizes DC and
lymphocyte effector cells at the tumor site. This may improve tumor antigen presentation and T
cell activation by utilizing the tumor as an in vivo source of antigen for DC. In order to develop DC-
based cancer therapies for intratumoral injection that could promote tumor antigen uptake and
presentation in situ, we constructed and characterized an adenoviral vector that expresses human
CCL-21 (AdCCL-21).
Results: Human monocyte derived DC were cultured in GM-CSF and IL-4 for 6 days. Following
AdCCL-21 transduction, CCL-21 protein production was assessed by ELISA on day 8. DC
transduced with AdCCL-21 at multiplicities of infection (MOIs) of 50:1 or 100:1 produced up to
210 ± 9 ng/ml and 278 ± 6.5 ng/ml /106 cells/48 hours, respectively. Following transduction, an
immature DC phenotype was maintained and an upregulation of the costimulatory molecule, CD86
was noted. In addition, supernatant from AdCCL-21-DC caused significant chemotaxis of
peripheral blood lymphocytes and mature DC.
Conclusions: These studies demonstrate that AdCCL-21-DC generate functional levels of CCL-
21 without adversely altering DC phenotype. These findings strengthen the rationale for further
investigation of AdCCL-21-DC as a DC-based therapy in cancer treatment.
Background
Tumor-associated antigens are expressed by many tumors,
including lung cancers, and can be presented to cytotoxic
T cells by antigen presenting cells (APCs) resulting in
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antitumor responses [1]. As a result of limited expression
of major histocompatibility complex (MHC) antigen and
costimulatory molecules, as well as production of
immune inhibitory cytokines, tumor cells are ineffective
APCs [2]. Therefore, recruitment of professional APCs to
the tumor site may be essential for generating specific
anti-tumor immune responses. Dendritic cells (DC) are
potent APCs fundamental in the activation of specific
immunity [3]. Advancements in the isolation and in vitro
propagation of DC have generated interest in their use in
cancer therapy. DC have been investigated as adjuvants to
cancer immunotherapy to stimulate tumor-specific anti-
gen presentation for promotion of T cell activation and
anticancer immunity [4–8].
Strategies employing DC in immunotherapy have
included DC pulsed with tumor antigen peptides, apop-
totic tumor cells, tumor lysates, or genetic modification of
DC with genes encoding tumor antigens or immunomod-
ulatory proteins [8–17]. There is evidence that DC trans-
duced with adenoviral vectors (AdV) have prolonged
survival and resistance to spontaneous and Fas-mediated
cell death [18]. This could result in the improved delivery
of immunotherapy. AdV transduction can also augment
the capacity of DC to induce protective antitumor immu-
nity [19]. In addition, enhanced local and systemic anti-
tumor effects have been demonstrated when AdV trans-
duced DC expressing cytokine genes have been injected
intratumorally [17,20–23].
The use of ex vivo-propagated DC genetically modified to
express chemokines that attract DC and lymphocyte effec-
tor cells to sites of tumor may improve tumor antigen
presentation and T cell activation by utilizing the tumor as
an in vivo source of antigen for dendritic cells. Chemok-
ines are a family of proteins involved in leukocyte chem-
otaxis and activation, and have been associated with the
regulation of angiogenesis [24,25]. CCL-21 is a CC chem-
okine expressed by high endothelial venules and in T cell
zones of spleen and lymph nodes that strongly attracts T
cells and mature DC [26–33]. CCL-21 recruits both Th1
lymphocytes and antigen-stimulated dendritic cells into T
cell zones of secondary lymphoid organs, co-localizing
the immune response elements and resulting in T cell acti-
vation [26]. In plt-/plt- mice with undetectable levels of
CCL-21, the homing of T cells and DC to secondary lym-
phoid organs has been shown to be significantly
decreased [34]. In addition to its immunotherapeutic
potential, CCL-21 has been found to have potent angi-
ostatic effects [35], thus adding further support for its use
in cancer therapy.
Based on these capacities, CCL-21 could be an important
protein for evaluation in cancer immunotherapy. Studies
using recombinant CCL-21 in mouse lung cancer models
have shown that intratumoral injection of recombinant
CCL-21 led to potent antitumor responses with complete
tumor eradication in 40% of treated mice [36]. In a spon-
taneous lung cancer model, recombinant CCL-21 injected
into the axillary lymph node region produced a marked
reduction in tumor burden with extensive lymphocytic
and DC infiltration of the tumors. The CCL-21 injected
mice also showed increased survival [37]. Intratumoral
injections of murine CCL-21 gene modified DC (murine
AdCCL-21-DC) into established murine lung tumors
resulted in complete tumor regression and enhanced pro-
tective immunity compared to mice treated with control
vector transduced DC or DC alone [23]. Similar results
have been shown in a murine melanoma model [20,21].
The anti-tumor efficacy of AdCCL-21-DC implies an
important role for DC as a vehicle to deliver CCL-21 to the
tumor.
Based on these preclinical results, we constructed and
characterized an adenoviral vector expressing human
CCL-21 (AdCCL-21) to be utilized for transduction of
human monocyte-derived DC (AdCCL-21-DC). We
hypothesized that this construct would effectively pro-
duce CCL-21 without compromising DC phenotype. In
addition, we proposed that human DC transduced with
AdCCL-21 would demonstrate enhanced chemokine-
dependent biologic activity evidenced by the capacity to
attract lymphocytes and APCs. Our results indicate that
AdCCL-21-DC generate biologically relevant levels of
CCL-21 without negatively altering DC phenotype.
Results
AdCCL-21 gene-modified human DC produce biologically 
active levels of CCL-21
On day 6 of culture, immature human monocyte-derived
DC (at 106 cells/ml) were transduced with AdCCL-21 at
various multiplicities of infection (MOIs, 50:1–10,000:1)
for 24–192 hours. Transduction was accomplished either
by the standard method (2 hours incubation at 37°C), or
by the centrifugation method (2000 × g at 37°C for 2
hours) as previously described [38,39]. CCL-21 protein
production was assessed by ELISA, and demonstrated
higher concentrations with increasing MOIs. Protein pro-
duction increased with escalating MOIs, and plateaued at
MOIs greater than 100:1. Cell viability significantly
decreased at MOIs greater than 500:1 (data not shown).
At relatively low MOIs of 50:1 and 100:1, 210 and 278 ng/
ml/106 cells/48 hours of CCL-21 protein was produced
respectively (Table 1). Moreover, DC transduction by the
centrifugation method led to 2.9 fold increase in CCL-21
protein secretion compared to the standard transduction
method (Table 1). Time course experiments revealed a
plateau of CCL-21 production at 48 hours with sustained
protein secretion at high levels (>190 ng/106 cells) up to
day 8 after transduction (day 14 of culture) (Figure 1).Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/35
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Table 1: CCL-21 production by AdCCL-21-DC
DC AdCCL-21-DC MOI 50:1 AdCCL-21-DC MOI 100:1 AdCV-DC MOI 100:1
ng/106 DC/48 hours
Standard Method 0.5 ± 0.24 *71 ± 15 *91.2 ± 5 0.5 ± 0.02
Centrifugation Method 0.67 ± 0.004 *210 ± 8.9 *278.2 ± 16.5 0.78 ± 0.05
*p ≤ 0.01; **p ≤ 0.0009
CCL-21 protein production by AdCCL-21-DC. DC propagated in vitro with GM-CSF and IL-4 were transduced with human AdCCL-21 or AdCV on 
day 6 of culture at MOIs 50:1 and 100:1. Transduction was accomplished by the standard incubation at 37°C (a) or by the centrifugation method (b) 
as described in materials and methods. CCL-21 protein concentration was determined in the supernatant of AdCCL-21 DC, AdCV-DC and NTDC 
by ELISA 48 hours after transduction. A 2.9 fold increase in CCL-21 protein production was achieved by the centrifugation method of DC 
transduction compared to the standard method. Values refer to CCL-21 protein concentration expressed in nanograms per million cells and are 
representative of three independent experiments. P values refer to significant differences of AdCCL-21-DC with AdCV-DC and control DC.
AdCCL-21-DC secretes CCL-21 up to 8 days after transduction Figure 1
AdCCL-21-DC secretes CCL-21 up to 8 days after transduction. Supernatant from non-transduced DC (DC), AdCV-DC and 
Ad-CCL-21-DC transduced on day 6 of culture at MOIs 50:1 and 100:1 was analyzed for CCL-21 protein secretion by ELISA in 
a time-course experiment. Values refer to SLC protein concentration expressed in nanograms per million cells at different 
time-points (24, 48, 96, and 192 hours after transduction). Although very limited amounts of CCL-21 protein were detected in 
control DC or AdCV-DC, the levels were consistent and significantly less than the concentrations produced by AdCCL-21-
DC.
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There were no significant differences noted in CCL-21
protein production when comparing LPS-matured and
immature DC (data not shown). For subsequent studies,
we assessed DC phenotype and function 48 hours follow-
ing adenoviral transduction at MOI 50:1 and 100:1 in
immature DC.
DC phenotype is maintained after transduction with 
AdCCL-21
DC, AdCCL-21-DC, and DC transduced with the control
adenoviral construct (AdCV) were characterized by flow
cytometry at 48 hours after transduction. The expression
of DC surface markers was not significantly altered by
transduction with AdCCL-21 or AdCV (AdCV-DC). The
immature DC phenotype was preserved in AdCV-DC and
AdCCL-21-DC without up-regulation of CD83, HLA-DR,
or CCR7 (Figure 2). We demonstrated an increase in the
expression of CD86 following transduction with either
AdCCL-21 or AdCV. The latter is consistent with previous
reports [19,40,41].
AdCCL-21-DC augments chemotaxis of PBL and mature 
DC
The migration of peripheral blood lymphocytes (PBL) to
AdCCL-21-DC was assessed by a standard transwell chem-
otaxis assay. Supernatants from AdCCL-21-DC, AdCV-
DC, and non-transduced DC (NTDC), as well as
recombinant CCL-21 (rCCL-21) were used to demon-
Phenotype of human DC transduced with AdCCL-21 Figure 2
Phenotype of human DC transduced with AdCCL-21. DC, Ad-CCl-21-DC and AdCV-DC were characterized by flow cytome-
try. On day 8, cells were stained with antibodies to cell surface markers conjugated to fluorochromes listed in Materials and 
Methods and FACS analysis was performed. Histograms show surface expression in non-transduced DC and AdCCl-21-DC 
transduced at MOI 50:1 and 100:1. Control DC in the first panels; Ad-CCL-21-DC at MOI in the second column; Ad-CCL21-
DC at MOI of 100:1 in the third column; and AdCV-DC in the final panels. Dotted lines represent isotype control and bold 
lines the surface marker staining. Results are representative of three independent experiments.
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strate this integral activity. 2 × 105 freshly isolated PBL,
labeled with a fluorescent probe, were allowed to migrate
through 3 µm pore inserts of the transwell plate. Total cell
migration was determined by measuring optical density
(OD). Supernatant from AdCCL-21-DC (producing 20
ng/ml/106 cells) induced enhanced chemotaxis of PBL
when compared to AdCV-DC supernatant, non-trans-
duced DC supernatant alone, or control medium (p <
0.002) (10% AB serum) (Figure 3). Furthermore, AdCCL-
21-DC promoted chemotaxis of LPS-matured DC (data
not shown).
Anti-CCL-21 antibody significantly inhibits the enhanced 
chemotaxis stimulated by AdCCL-21-DC
We evaluated the contribution of CCL-21 to the enhanced
function of AdCCL-21-DC compared to AdCV-DC or
NTDC. A pre-titered neutralizing concentration of CCL-21
antibody was added to AdCCL-21-DC supernatant or
recombinant CCL-21 and incubated for 30 minutes. The
chemokine-dependent activity of AdCCL-21-DC was
assessed by measuring the migration of T2 cells to AdCCL-
21-DC and NTDC supernatants or rCCL-21 in the pres-
ence or absence of anti-CCL-21 antibody. T2 is a T/B
hybridoma that lacks HLA class II antigen, but expresses
AdCCL-21-DC augments PBL chemotaxis Figure 3
AdCCL-21-DC augments PBL chemotaxis. Ad-CCL-21-DC, AdCV, NTDC, and recombinant CCL-21 were used to investigate 
the induction of migration of PBL in response to AdCCL-21-DC. 2 × 105 freshly isolated PBL were labeled with 5 µm cell 
tracker™ green 5-chloromethylfluorescein diacetate and loaded in the upper chamber of a Transwell apparatus fitted with 3 
µm pre size membrane inserts. Supernatant from NTDC, AdCCL21-DC (producing 20 ng/ml/106 cells/48 hours CCL-21 pro-
tein) and AdCV-DC were added to the lower chamber. The OD of migrated cells was measured after 2 hours incubation at 
37°C by a fluorescence plate reader. Values are expressed as relative migration versus control (10% AB medium). The bar on 
the far right indicates chemotaxis to recombinant CCL-21 at 100 ng/ml. Results are representative of three independent 
experiments.
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HLA.A2 molecules. These cells are often used as APCs
when evaluating specific cytotoxic T lymphocyte
responses, and were chosen to evaluate chemotaxis of
APCs to AdCCL-21-DC. Our results showed that anti-
CCL-21 antibody efficiently blocked the chemotactic
activity of recombinant CCL-21 (data not shown). More-
over, the enhanced attraction of T2 cells observed with
AdCCL-21-DC supernatant was significantly inhibited by
the addition of anti-CCL-21 antibody. (Figure 4). Our
data shows a partial reversal of the chemoattractive prop-
erties of AdCCL-21-DC using anti-CCL-21 antibody.
Other proteins and chemokines with attractant capacities
exist in DC supernatants, and these likely account for the
incomplete inhibition of cell migration when anti-CCL-
21 is added to AdCCL-21-DC. Chemotaxis of AdCCL-21-
Chemotactic activity of AdCCL-21-DC is blocked by anti-CCL-21 neutralizing antibody Figure 4
Chemotactic activity of AdCCL-21-DC is blocked by anti-CCL-21 neutralizing antibody. T2 cells were used as APCs in tran-
swell Chemicon assays. 2.0 × 105 T2 cells in 100 µl serum free medium were added to the upper chamber of the transwell 
plate. 150 µl of supernatant from AdCCL-21-DC were pre-incubated for 30 minutes with anti-CCL-21 antibody or with a con-
trol antibody prior loading to the lower chamber of the Chemicon apparatus. After 2 hours incubation at 37°C, cells were 
lysed and stained with a green fluorescent dye according to the manufacturer's instructions. Total cell migration was deter-
mined by measuring the fluorescence of cells collected from the lower chamber and the bottom of the inserts using a fluores-
cence plate reader with 480/520 nm filter set. Values are expressed as relative migration versus the control (10% AB medium) 
and are representative of three independent experiments.
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DC was not inhibited following addition of control
antibody.
AdCCL-21 transduction decreases immunosuppressive 
cytokine production
Previous studies have indicated that that adenoviral vector
transduction of DC stimulates enhanced effector cell
activity [19], in part through increased IL-12 production.
We investigated the effects of AdCCL-21 and AdCV trans-
duction on DC production of IL-12 and IL-10 after stimu-
lation with IFNγ and LPS or LPS alone, respectively. We
found that AdCV-DC and AdCCL-21-DC maintained the
capacity to secrete IL-12 with decreased production of IL-
10 (Figure 5). Secretion of IL-10 was decreased by 40–
49% after AdCCL-21 or AdCV transduction.
Discussion
The ability of DC to capture, process, and present antigens
with subsequent activation of CD4+ and CD8+ T lym-
phocytes makes them ideal adjuvants in immunotherapy
approaches to cancer. In animal models, intratumoral
injection of AdV transduced DC expressing cytokine genes
has generated enhanced anti-tumor effects compared with
NTDC or DC transduced with control vector [17,20–23].
We have characterized DC following transduction with an
adenoviral vector expressing the CCL-21 gene. At the
MOIs evaluated, DC maintained their immature pheno-
type without significantly up-regulating CD83 or CCR7
expression. Our findings that the DC expression of CD86
is increased following adenoviral transduction is consist-
ent with prior reports [19,40,41]. These results suggest
that DC transduced with adenovirus will have improved
costimulatory capacities. In addition, supernatant from
AdCCL-21-DC augmented the chemoattraction of periph-
eral blood lymphocytes and LPS-stimulated DC when
compared to migration to supernatants from non-trans-
duced DC or DC transduced with control adenoviral vec-
tor. These studies demonstrate that AdCCL-21
transduction of monocyte-derived DC yield cells with
enhanced capacity to attract PBL and APCs. Thus, intratu-
moral administration of gene modified DC to express
CCL-21 may prove to be an effective strategy of immuno-
therapy for achieving tumor antigen presentation utilizing
the tumor as an in vivo source of antigen for DC [17].
CCL-21 recruits both T lymphocytes and antigen-stimu-
lated DC into T cell zones of secondary lymphoid organs.
This creates a convergence of the immune response ele-
ments to sites of CCL-21 production, resulting in T cell
activation and antitumor effects [26,36]. CCL-21 acts
through CCR7, a chemokine receptor belonging to a sub-
family of G protein-coupled seven-transmembrane recep-
tors [42]. CCR7 is integral in mediating the homing of DC
and naïve and activated T lymphocytes to secondary lym-
phoid organs. This creates an environment in which co-
localization of T cells and mature antigen-loaded DC can
occur [43].
We found that intratumoral injection of murine AdCCL-
21-DC was effective in eradicating established tumors and
promoting long-term anti-tumor immunity in a murine
lung cancer model [23]. We have developed the use of
intratumoral administration of DC that have been modi-
fied with cytokine genes ex vivo, and this approach
achieves tumor antigen presentation by utilizing the
tumor as an in vivo source of antigen for DC [17]. In con-
trast to in vitro immunization with purified peptide anti-
gen, autologous tumor has the capacity to provide the DC
administered at the tumor site access to the entire reper-
toire of available antigens in situ. This may increase the
likelihood of a response and reduce the potential for
tumor resistance due to phenotypic modulation.
Increased IL-10 at the tumor site has been reported to sup-
press immune responses [44,45]. Our finding that trans-
duction of DC with AdCV or AdCCL-21 resulted in
decreased IL-10 production while maintaining IL-12
secretion when compared to non-transduced DC, is con-
sistent with an overall immunostimulatory effect of the
adenovirus upon transduction of DC [19]. The ability to
polarize the immune response to a Th1 phenotype may
potentiate the antitumor immune response seen with
intratumoral injection of AdCCL-21-DC.
Our investigations have revealed that the transduced DC
maintain their immature phenotype. This has important
implications for its use as a potential intratumoral therapy
in cancer because immature DC are efficient in antigen
uptake. Following antigen capture, DC mature and
develop improved migration, antigen presentation, and T
cell stimulation [46]. Mature DC are potent APCs, express-
ing high levels of MHC class II, adhesion, and costimula-
tory molecules on their surface. Surface expression of
CCR7 is also enhanced and mature DC thus gain the
capacity to respond to CCL-21 [47,48]. Clinical trials
employing mature DC injected by subcutaneous and
intranodal routes have suggested that these cells may be
effective in eliciting T cell responses [49–51]. Our
approach involves the transduction of immature DC with
AdCCL-21 to stimulate the migration of mature DC and T
lymphocytes to the site of injection. We propose that
introducing immature DC to the site of tumor will create
the optimal environment for effective antigen uptake,
using the tumor as an in vivo source of antigen [17,23].
CCL-21 expression could then promote movement of
mature DC and Th1 lymphocytes to the site of tumor for
potential cross-presentation and activation of T cells for
potent anti-tumor immune responses.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/35
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IL-12 p70 and IL-10 production by AdCCL-21-DC Figure 5
IL-12 p70 and IL-10 production by AdCCL-21-DC. Human monocyte-derived DC were transduced with AdCCL-21 and AdCV 
at an MOI of 50:1 and 100:1 at 37°C for 2 hrs by the standard method. 1.0 × 105non-transduced DC (Mo-DC), AdCCL-21-DC 
and AdCV-DC were plated into a 24 well plate in 1 ml of culture medium in presence or absence of the appropriate stimula-
tion for IL-12p70 (γ-IFN and LPS) or IL-10 (LPS). After 48 hrs induction, supernatants from stimulated and non-stimulated DC 
(non-transduced DC, AdCCL-21-DC and AdCV-DC) were harvested and measured for IL-12p70 and IL-10 concentrations by 
specific ELISA. Values refer to cytokine concentrations expressed in nanograms per million cells 48 after stimulation (96 hrs 
after transduction) and are representative of three separate experiments.
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Conclusions
AdCCL-21-DC may potentiate the induction of anti-
tumor immune responses by augmenting antigen presen-
tation and T lymphocyte activation. Thus, in this system
the transferred DC expressing CCL-21 may act to enhance
the generation of anti-tumor immunity because the tumor
can serve as the in vivo source of antigen for DC. Our
results demonstrate that AdCCL-21-DC generate biologi-
cally functional levels of CCL-21 without impairing DC
phenotype. This data, revealing the biological activity of
AdCCL-21-DC, paired with our results of intratumoral
injection of AdCCL-21-DC in murine lung cancer models
[23], supports further investigation of this approach as a
novel genetic immunotherapy for cancer treatment.
Methods
Preparation of adenoviral vector expressing human CCL-
21
The adenoviral construct (AdCCL-21) is an E1-deleted,
replication-deficient adenoviral serotype 5 vector encod-
ing a 491 bp-containing human CCL-21 cDNA (Figure 6).
The coding sequence 59–453, was amplified by PCR with
the following primers: 5' primer 5'-CTTGCAGCT-
GCCCACCTCAC (1–20) and 3' primer 5'-TCTCCAG-
GGCTCCAGGCT-GC-3 (491-472). The CCL-21 gene was
amplified and cloned into pAC-CMVpLpA (originally
cloned by Dr. R. Gerard, and was acquired from Dr. J.
Economou at UCLA, Los Angeles, CA) to generate pAC-
CMV-CCL-21pA. pAC-CMV-CCL-21pA was co-transfected
with pJM-17 (plasmid containing the E1-deleted Ad-
genome, obtained from Dr. J. Economou) into 293 cells
(American Type Culture Collection [ATCC] Manassas,
VA) to yield recombinant E1-deleted adenovirus (AdCCL-
21) following homologous recombination. The control
vector (AdCV) did not contain the CCL-21 cDNA insert.
Clones of AdCCL-21 and AdCV were obtained by limiting
dilution analysis of the ability of the medium to induce a
cytopathic effect on fresh 293 cells. Clones were con-
firmed by CCL-21 specific ELISA. Viral stocks were then
obtained by amplification of the 293 cells followed by
CsCl purification, dialysis, and storage as a glycerol (10%
volume/volume) stock at -80°C. The titer of each viral
stock was routinely 1011–1012 plaque forming units by
plaque assay on 293 cells. Contamination with wild type
recombinant adenovirus was assessed for each viral stock
by plaque assay on Hela cells and was consistently
negative.
Generation of dendritic cells
The use of leukocyte-enriched buffy coat from healthy
donors was approved by the UCLA IRB, and informed
consent was obtained from all donors. Peripheral blood
mononuclear cells (PBMC) were obtained from leuko-
cyte-enriched buffy coat from healthy donors by centrifu-
gation with Ficoll-Paque™ Plus (Amersham Biosciences,
Uppsala, Sweden) and the light density fraction from the
42.5–50% interface was recovered. The cells were resus-
pended at 2 × 106 cells/ml in RPMI 1640 supplemented
with 20 mM HEPES buffer (Cellgro, Mediatech, Herdon,
VA), 100 units/ml Penicillin-Streptomycin, and 2 mM
glutamine (Invitrogen, Carlsbad, CA). The cells were
allowed to adhere to tissue culture flasks for 2 hours at
37°C. After incubation, the non-adherent cells were
removed, and adherent cells were washed twice in Dul-
becco's PBS without Ca2+ and Mg2+(Cellgro). Cells were
then cultured for 6 days in complete RPMI medium with
10% human AB serum (Gemini Bio-Products, Wood-
lands, CA), recombinant human GM-CSF (75 ng/ml),
(Peprotech Inc., Rocky Hill, NY, specific activity ≥ 1 × 107
units/mg) and recombinant human IL-4 (75 ng/ml)
(Peprotech Inc., specific activity ≥ 5 × 106 units/mg).
Cytokines were added every 2–3 days during culture.
Adenoviral transduction of human DC
Monocyte-derived DC were transduced with human
AdCCL-21 or AdCV expression vectors on day 6 of culture
either by the standard method of incubation at 37° for 2
hours or by centrifugation method as previously
described [38,39]. Briefly 1.0 × 106 DC, resuspended in
300 µl DPBS (Invitrogen, Carlsbad, CA) containing Ad-
CCL-21 or AdCV at various MOIs (from 5:1 to 10,000:1)
were incubated at 37°C for 2 hours or centrifuged at 2000
× g at 37°C for two hours (Microfuge Eppendorf 5415R,
Fisher Scientific, Pittsburgh, PA). NTDC, AdCCL-21-DC
and AdCV-DC were then washed twice, resuspended in
complete medium and incubated at 37°C for 24 to 192
hours. The cumulative CCL-21 protein production was
measured daily up to 8 days following transduction.
Immunophenotypic analysis and cell viability by flow 
cytometry
DC, AdCCL-21-DC, and AdCV-DC were characterized by
flow cytometry on day 8 of culture. The following panel of
monoclonal antibodies was used: HLA-DR-FITC (fluores-
cein isothiocyanin), CD40-PE (phycoerytrin), CD80-PE,
CD86-PE, HLA-DR-FITC (BD Biosciences PharMingen,
San Diego, CA), and CD83-FITC (Coulter Immunology,
Hialeah, FL). All antibodies were used with appropriate
isotype controls (BD Biosciences, La Jolla, CA). Evalua-
tion of CCR7 surface expression was performed by a dou-
ble step staining method using purified anti-human CCR7
(BD Biosciences PharMingen) followed by biotin-strepta-
vidin staining. Briefly, DC were first labeled with purified
mouse anti-human CCR7 monoclonal antibody for 30
minutes at room temperature. Cells were washed twice in
FACS buffer (PBS, 2% FBS) and incubated with a biotin-
conjugated rat anti-mouse IgM monoclonal antibody (BD
PharMingen). After two washes in FACS buffer cells were
stained with streptavidin PE (BD PharMingen). Viability
of the cells was measured using 7-Amino-Actinomycin-DMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/35
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(7-AAD) (Calbiochem, San Diego, CA). A live gate was set
by forward and side scatter and 7-AAD staining. 10,000
cells with high forward scatter and high side scatter were
counted. Events were acquired by FACS using a LSR flow
cytometer (Becton, Dickenson, and Co. Biosciences
Immunocytometry System, San Jose, CA) in the Univer-
sity of California, Los Angeles, Jonsson Comprehensive
Cancer Center Flow Cytometry Core Facility. Data analy-
sis was performed by CELLQuest software.
CCL-21 ELISA
CCL-21 protein concentration from NTDC, AdCCL-21-
DC and AdCV-DC supernatant was determined by CCl-
21-specific ELISA. Briefly, 96-well Costar (Cambridge,
MA) plates were coated overnight with 2 µg/ml of anti-
CCL-21 monoclonal antibody (Peprotech Inc., Rocky
Hill, NY). After four washes in PBS-0.05% Tween-20, the
unbound material was removed and the plate was incu-
bated with a blocking buffer (10% fetal bovine serum,
Gemini Bioproducts, Woodlands, CA) in PBS for 30 min-
utes. After four washes, the plate was incubated with CCL-
21 standard or with the sample supernatant for one hour
and excess antigen was washed off with PBS/Tween. The
plate was then incubated with avidin-conjugated to horse-
radish-peroxidase for 20 minutes in the dark. After wash-
ing to remove all unbound reagents, the plate was
incubated with a substrate solution for 20 minutes in the
dark. Reactions were stopped by adding 1-M sulfuric acid
and the optical density was read at 450 nm in a microplate
reader (Molecular Dynamics, Sunnyvale, CA). The sensi-
tivity of the CCl-21 assay was 156 pg/ml.
Chemotaxis assay
The biological function of supernatant derived from
AdCCL-21-DC, AdCV-DC and NTDC was assessed in a
standard chemotaxis assay. We measured the migration of
PBL through a 24-well transwell plate fitted with 3 µm
polycarbonate membrane inserts. 2 × 105 freshly isolated
PBL by Ficoll-Paque density-gradient separation were
labeled with 5 µm cell tracker™ green 5-chloromethylflu-
orescein diacetate (CMFDA, Molecular Probes Inc.,
Eugene, OR) for 45 minutes, washed and loaded in the
upper chamber of the transwell plate in 100 µl serum-free
medium. 500 µl of supernatant from 106 AdCCL-21-DC,
AdCV-DC and NTDC were added to the lower chamber.
10% AB medium and 100 ng/ml recombinant CCL-21
(R&D Systems, Minneapolis, MN) were used as negative
and positive controls, respectively. Cells were incubated
for 2 hours at 37°C. The migrated cells were recovered
from the lower chamber, centrifuged, and transferred into
a 96-well flat-bottomed plate (Costar). Total cell migra-
tion was determined by measuring optical density (OD)
of migrated cells using Wallac 1420 (Perkin Elmer, Bos-
ton, MA) fluorescent plate reader set at excitation/emis-
sion wavelengths of 485/530 nm.
Chemotaxis blocking assay
Chemotaxis blocking assays were performed using QCM™
chemotaxis 96-well plates fitted with 3 µm membrane
inserts (Chemicon International, Inc., Temecula, CA)
according to the manufacturers instructions. Briefly, 2 ×
10 5 cells/ml T2 cells (a gift from Dr. J. Economou, David
Geffen School of Medicine at UCLA, Los Angeles, CA),
were resuspended in serum-free medium and loaded in
the upper chamber of a QCM™ apparatus. 150 µl of super-
natant derived from AdCCL-21-DC were pre-incubated
with neutralizing concentrations of anti-CCL-21 antibody
(R&D Systems) or Chrompure goat IgG whole molecule
as the control antibody (Jackson Immunoresearch, West-
grove, PA) for 30 minutes at room temperature. Similarly
100–600 ng/ml recombinant CCL-21 was pre-incubated
with 4–8 µg/ml anti-CCL-21 or control antibody. The
neutralizing concentration of anti-CCL-21 antibody
(R&D Systems) used in these studies (4 µg/ml and 8 µg/
ml) was based on the ND50 (50% maximum inhibition
of cytokine activity when CCL-21 is present at a concen-
tration high enough to elicit maximum response) of goat
anti-human CCL-21 as reported by the manufacturer (4 –
8 µg/ml anti-CCL-21 with 500 ng/ml rCCL-21). The pre-
incubated samples were then added to the lower chamber
of the QCM™ apparatus. In addition, 150 µl of superna-
tant without antibody from AdCCL-21-DC, 10% AB
medium or 100–600 ng/ml recombinant CCL-21 (R & D
Systems) were added to the lower chambers as chemotaxis
controls. After 2 hours incubation at 37°C migrated cells
were recovered from the lower chamber and from the
inserts according to the manufacturer's instructions. Cells
were lysed and stained with a green fluorescent dye
(CyQuant GR dye, Molecular Probes) for 15 minutes at
room temperature. Cells were transferred to a 96-well flat-
bottomed ELISA microplate (Costar) and fluorescence
was read at 480/525 nm using Wallac 1420 fluorescent
plate reader (Perkin Elmer).
IL-10 and IL-12p70 ELISA
To induce IL-12 production, (1.0 × 105) AdCCL21-DC,
AdCV-DC and control DC were primed with 50 ng/ml γ-
IFN (Peprotech Inc.) for 2 hours and then stimulated with
1 µg/ml LPS (Sigma) for 48 hours. To induce IL-10 pro-
duction, (1.0 × 105) AdCCL21-DC, AdCV-DC and control
DC were stimulated with 1 µg/ml LPS for 48 hours. IL-12
p70 and IL-10 concentrations were measured in the super-
natant of either unstimulated or stimulated DC by specific
ELISA as previously described [52]. For detection of IL-
12p70, antibodies and standards were purchased from
R&D Systems Inc. For detection of IL-10, antibodies and
standards were obtained from BD Biosciences. The sensi-
tivity of the ELISA for IL-12 p70 and IL-10 was < 1 pg/ml.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/35
Page 11 of 13
(page number not for citation purposes)
Statistical Analysis
The unpaired two-tailed Student's t test was used to com-
pare differences in DC and AdCCL-21-DC groups. P-val-
ues = 0.05 were considered significant.
List of abbreviations
The abbreviations used are: DC, dendritic cells; CCL-21/
SLC, secondary lymphoid tissue chemokine; GM-CSF,
granulocyte macrophage colony-stimulating factor; IL,
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presenting cell; MHC, major histocompatibility complex;
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